SGMO

0.1342

24.44% -0.0434

After Hours: .13 -0.0042 -3.13%

Sangamo Therapeutics Inc (SGMO)

Overview News Price History Option Chain Financials Discussions Forecast

Sangamo Therapeutics Inc stock is traded at $0.1342, with a volume of 13.82M. It is down -24.44% in the last 24 hours and down -51.83% over the past month. SANGAMO THERAPEUTICS INC

Previous Close:

$0.1776

Open:

$0.12

24h Volume:

13.82M

Relative Volume:

1.47

Market Cap:

$55.60M

Revenue:

$39.55M

Net Income/Loss:

$-122.93M

P/E Ratio:

-0.3034

EPS:

-0.4423

Net Cash Flow:

$-97.31M

1W Performance:

+1.05%

1M Performance:

-51.83%

6M Performance:

-70.86%

1Y Performance:

-78.07%

1-Day Range:

$0.1131

$0.148

1-Week Range:

$0.1131

$0.217

52-Week Range:

$0.1131

$0.766

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name

Sangamo Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

@sangamotx

Next Earnings Date

2026-05-11

Latest SEC Filings

SGMO's Discussions on Twitter

Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMO Sangamo Therapeutics Inc	0.1342	73.58M	39.55M	-122.93M	-97.31M	-0.4423
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Barclays	Overweight → Equal Weight
Dec-13-24	Upgrade	Truist	Hold → Buy
Dec-10-24	Reiterated	H.C. Wainwright	Buy
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Jun-13-22	Resumed	Wedbush	Neutral
May-04-21	Initiated	RBC Capital Mkts	Outperform
Jan-07-21	Resumed	Guggenheim	Neutral
Jan-06-21	Initiated	Stifel	Hold
Dec-16-20	Resumed	H.C. Wainwright	Buy
Sep-08-20	Initiated	BofA Securities	Buy
Jul-07-20	Initiated	SunTrust	Buy
Aug-26-19	Initiated	H.C. Wainwright	Buy
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-04-15	Initiated	Wells Fargo	Outperform
Oct-23-15	Resumed	Jefferies	Buy
May-03-13	Initiated	BioLogic Equity Research	Sell
Feb-23-11	Reiterated	JMP Securities	Mkt Outperform
Jul-29-10	Reiterated	Wedbush	Outperform
Oct-19-09	Initiated	Brean Murray	Sell
Oct-07-09	Reiterated	Leerink Swann	Outperform
Aug-25-09	Reiterated	JMP Securities	Mkt Outperform

View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

05:35 AM

Non-controlling/minority interest of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

05:35 AM

05:26 AM

Enterprise value to EBITDA ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

04:24 AM

04:11 AM

Net debt of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

04:11 AM

04:08 AM

Cost of goods sold of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

04:08 AM

04:07 AM

Sangamo Therapeutics, Inc. Balance Sheet – OTC:SGMO - TradingView

04:07 AM

04:05 AM

Operating income of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

04:05 AM

04:04 AM

Sangamo Therapeutics, Inc. Revenue Breakdown – OTC:SGMO - TradingView

04:04 AM

Net current asset value per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

04:04 AM

03:46 AM

Long term debt to total equity ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

03:46 AM

03:45 AM

EBIT per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

03:45 AM

03:43 AM

EBITDA margin % of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

03:43 AM

03:42 AM

Sangamo Therapeutics, Inc. Income Statement – OTC:SGMO - TradingView

03:42 AM

03:37 AM

Net income of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

03:37 AM

03:35 AM

Sangamo Therapeutics, Inc. Earnings and Revenue – OTC:SGMO - TradingView

03:35 AM

May 04, 2026

Sangamo Stock Jumps Before Nasdaq Exit: Why SGMO Investors Are Watching May 5 - TechStock²

May 04, 2026

Sangamo Therapeutics (SGMO) to Release Earnings on Monday - MarketBeat

May 04, 2026

May 03, 2026

Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from NASDAQ Composite Index - marketscreener.com

May 03, 2026

May 01, 2026

Sangamo Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo

May 01, 2026

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat

May 01, 2026

SGMO Forecast, Price Target & Analyst Ratings | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill

May 01, 2026

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Sangamo Therapeutics 2025 Executive Compensation, Stock Awards, and Corporate Objectives Overview - Minichart

Apr 30, 2026

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) - The Manila Times

Apr 30, 2026

SGMO Financials: Income Statement, Balance Sheet & Cash Flow | Sangamo Therapeutics Inc - Stock Titan

Apr 30, 2026

H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Therapeutics (SGMO) - The Globe and Mail

Apr 30, 2026

Apr 29, 2026